Sickle cell anemia treatment safely lowers disease burden in African children

(Cincinnati Children's Hospital Medical Center) A daily hydroxyurea pill may bring relief for children living with the painful and deadly blood disease sickle cell anemia (SCA) in resource-challenged sub-Saharan Africa, where the disease is prevalent and health care is suboptimal. This is what a multinational clinical trial called REACH discovered when it tested daily hydroxyurea treatment in 606 children between the ages of 1 and 10 years old. Study data are published in the New England Journal of Medicine.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news